Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 301–400 of 831
Byrne, G., O’Rourke, S. M., Alexander, D. L., Yu, B., Doran, R. C., Wright, M., Chen, Q., Azadi, P., & Berman, P. W. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2005817 · Cited by 46
Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
Brouwer, P. J. M., Antanasijevic, A., Ronk, A. J., Müller-Kräuter, H., Watanabe, Y., Claireaux, M. A. F., Perrett, H. R., Bijl, T. P. L., Grobben, M., Umotoy, J. C., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.018 · Cited by 50
“Even though side chains were not explicitly built, the high amount of tyrosine residues was readily discernible on the LAVA01 heavy chain, mediating interactions with glycan residues, similar to several HIV-1 bNAbs.(36,37) The location of the epitope provides the basis for a potential neutralization mechanism for LAVA…”
BackgroundSelf-citationvan den Kerkhof, T. L. G. M., Feenstra, K. A., Euler, Z., van Gils, M. J., Rijsdijk, L. W. E., Boeser‐Nunnink, B., Heringa, J., Schuitemaker, H., & Sanders, R. W. (2013) · Retrovirology · doi:10.1186/1742-4690-10-102 · Cited by 44
“To this structure we added the V1V2 loops from 3U4E [64] and using 1GCG [127] to obtain an overlap with the 3JWD structure; as well as the V3 and V4 regions from 2B4C [128].”
Vigdorovich, V. I., Oliver, B. G. G., Carbonetti, S., Dambrauskas, N., Lange, M. D., Yacoob, C., Leahy, W., Callahan, J., Stamatatos, L., & Sather, D. N. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.42 · Cited by 41
Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies
Moore, P. L., Gorman, J., Doria‐Rose, N. A., & Morris, L. (2017) · Immunological Reviews · doi:10.1111/imr.12501 · Cited by 41
Self-citationNguyen, D. N. P., Xu, B., Stanfield, R. L., Bailey, J. K., Horiya, S., Temme, J. S., Leon, D. R., LaBranche, C. C., Montefiori, D. C., Costello, C. E., et al. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00588 · Cited by 42
Self-citationStrategies and Tactics for the Development of Selective Glycan-Binding Proteins
Ward, E. M., Kizer, M. E., & Imperiali, B. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00880 · Cited by 45
Anti-glycan antibodies: roles in human disease
Temme, J. S., Butler, D. L., & Gildersleeve, J. C. (2021) · Biochemical Journal · doi:10.1042/bcj20200610 · Cited by 48
Emerging concepts on T follicular helper cell dynamics in HIV infection
Pissani, F., & Streeck, H. (2014) · Trends in Immunology · doi:10.1016/j.it.2014.02.010 · Cited by 45
“In most patients, bNAbs develop only after years of chronic infection[9, 11, 12] and show remarkable properties including extremely high levels of SHM[10, 16, 68, 69], long CDR3 regions[70], and, in certain cases, polyreactivity[71].”
A Fusion Intermediate gp41 Immunogen Elicits Neutralizing Antibodies to HIV-1
Lai, R., Hock, M., Radzimanowski, J., Tonks, P., Hulsik, D. L., Effantin, G., Seilly, D. J., Dreja, H. S., Kliche, A., Wagner, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569566 · Cited by 44
Rawi, R., Rutten, L., Lai, Y., Olia, A. S., Blokland, S., Juraszek, J., Shen, C., Tsybovsky, Y., Verardi, R., Yang, Y., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108432 · Cited by 37
Self-citationSaunders, K. O., Edwards, R. J., Tilahun, K., Manne, K., Lu, X., Cain, D. W., Wiehe, K. J., Williams, W. B., Mansouri, K., Hernandez, G. E., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo5598 · Cited by 39
Self-citationAntigenic Properties of the HIV Envelope on Virions in Solution
Ray, K., Mengistu, M., Lewis, G. K., Lakowicz, J. R., & DeVico, A. L. (2013) · Journal of Virology · doi:10.1128/jvi.03048-13 · Cited by 39
“The available information (60, 61, 85) indicates that PG9 may bind envelope trimers in a range of orientations, some of which may explain our observations.”
ResultPreferred conformations ofN-glycan core pentasaccharide in solution and in glycoproteins
Jo, S., Qi, Y., & Im, W. (2015) · Glycobiology · doi:10.1093/glycob/cwv083 · Cited by 41
“These recognition events require specific carbohydrate structures and are sensitive to small differences in carbohydrate sequence or conformation (Siebert et al. 2003; McLellan et al. 2011; Rose 2012).”
BackgroundZolla‐Pazner, S., Powell, R. L. R., Yahyaei, S., Williams, C. A. U., Jiang, X., Li, W., Lu, S., Wang, S., Upadhyay, C., Hioe, C. E., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01403-16 · Cited by 38
“In contrast, the flexibility of the V1V2 regions present in V1V2YU2-1FD6 (clade B), V1V2ZM109-1FD6 (clade C), and the N160K mutant of V1V2ZM109-1FD6 was constrained by its placement in the 1FD6 scaffold (49).”
InfluentialJiang, X., Totrov, M. M., Li, W., Sampson, J. M., Williams, C. A. U., Lü, H., Wu, X., Lu, S., Wang, S., Zolla‐Pazner, S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01409-16 · Cited by 39
“The scaffold molecule V1V2(ZM109)-1FD6 used in crystallization with PG9 and PG16 (33) naturally carries the V2q type of epitopes.”
BackgroundMethodInfluentialMujib, S., Liu, J., Rahman, A. K. M. N.-U., Schwartz, J. A., Bonner, P., Yue, F. Y., & Ostrowski, M. (2017) · Journal of Virology · doi:10.1128/jvi.00634-17 · Cited by 44
“PG16 and PGT145, both targeting the V1/V2 domain (27, 33), also displayed enhanced recognition of”
BackgroundPrediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
Magaret, C. A., Benkeser, D. C., Williamson, B. D., Borate, B. R., Carpp, L. N., Georgiev, I. S., Setliff, I., Dingens, A. S., Simon, N., Carone, M., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006952 · Cited by 42
“A glycan at this position has been hypothesized as being important for recognition by other bnAbs [57], but to the best of our knowledge this is the first report to associate N156 with sensitivity to neutralization by VRC01.”
Self-citationPritchard, L. K., Spencer, D. I. R., Royle, L., Vasiljević, S., Krumm, S. A., Doores, K. J., & Crispin, M. (2015) · Journal of Virology · doi:10.1128/jvi.00230-15 · Cited by 41
Capacity for Infectious HIV-1 Virion Capture Differs by Envelope Antibody Specificity
Liu, P., Williams, L. D., Shen, X., Bonsignori, M., Vandergrift, N., Overman, R. G., Moody, M. A., Liao, H., Stieh, D. J., McCotter, K. L., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03765-13 · Cited by 38
“PG9, PG16, and CH01 (target Env V1/V2 and V3 region [15, 16]),”
Self-citationReconstituted B cell receptor signaling reveals carbohydrate-dependent mode of activation
Villar, R. F., Patel, J., Weaver, G. C., Kanekiyo, M., Wheatley, A. K., Yassine, H. M., Costello, C. E., Chandler, K. B., McTamney, P. M., Nabel, G. J., et al. (2016) · Scientific Reports · doi:10.1038/srep36298 · Cited by 35
Self-citationMax Bergmann lecture Protein epitope mimetics in the age of structural vaccinology
Robinson, J. A. (2013) · Journal of Peptide Science · doi:10.1002/psc.2482 · Cited by 43
Davenport, T. M., Gorman, J., Joyce, M. G., Zhou, T., Soto, C. S., Guttman, M., Moquin, S. A., Yang, Y., Zhang, B., Doria‐Rose, N. A., et al. (2016) · Structure · doi:10.1016/j.str.2016.06.012 · Cited by 44
“If CAP256-VRC26 antibodies interact with Env in a manner similar to CH03 or PG9/PG16, as most of the available data suggest, then the differences in dynamics within the CDRH2/FW3 region would be reasonably positioned to affect CAP256-VRC26 binding to Env by modifying the antibody’s interactions with these glycans (Fig…”
InfluentialSelf-citationKhan, S. N., Sok, D., Tran, K., Movsesyan, A., Dubrovskaya, V., Burton, D. R., & Wyatt, R. T. (2018) · Journal of Virology · doi:10.1128/jvi.00384-18 · Cited by 40
Self-citationBroadly neutralizing antibodies and vaccine design against HIV-1 infection
Wang, Q., & Zhang, L. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0721-9 · Cited by 44
Upadhyay, C., Feyznezhad, R., Cao, L., Chan, K.-W., Liu, K., Yang, W., Zhang, H., Yolitz, J., Arthos, J. A., Nadas, A. J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009185 · Cited by 37
“The V2q epitopes also include glycans at positions N156 or N173 and N160 on the V1V2 apex [16,26], which together with N197 and N276 glycans create the conserved ‘trimer-associated mannose patch’ (TAMP).”
BackgroundInfluentialSelf-citationMarchetti, R., Dillon, M. J., Burtnick, M. N., Hubbard, M., Kenfack, M. T., Blériot, Y., Gauthier, C., Brett, P. J., AuCoin, D. P., Lanzetta, R., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00502 · Cited by 37
Spurrier, B., Sampson, J. M., Górny, M. K., Zolla‐Pazner, S., & Kong, X. (2014) · Journal of Virology · doi:10.1128/jvi.03153-13 · Cited by 36
“The data demonstrated that the region recognized by the V2q MAbs and the V2p MAbs includes residues 168 to 173; however, the conformations that they recognize differ: PG9 and PG16 bind to this region as a -strand, while CH58 and CH59 bind to this region as an -helix or a coil.”
BackgroundMethodInfluentialMann, A. M., Friedrich, N., Krarup, A., Weber, J., Stiegeler, E., Dreier, B., Pugach, P., Robbiani, M., Riedel, T., Moehle, K., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00152-13 · Cited by 38
“The preference of DARPins for recognizing structural components could be advantageous in selecting HIV envelope-directed inhibitors, particularly as recent findings of potent broadly active neutralizing antibodies revealed a high prevalence of antibodies recognizing conformational inter- and intraprotomer loop-spannin…”
BackgroundNakamura, G. R., Fonseca, D. P. A. J., O’Rourke, S. M., Vollrath, A. L., & Berman, P. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039045 · Cited by 42
“The structure of a scaffold comprising the V1 and V2 domains of gp120 bound to the broadly neutralizing PG9 MAb has recently been elucidated”
BackgroundCryptic Determinant of α4β7 Binding in the V2 Loop of HIV-1 gp120
Tassaneetrithep, B., Tivon, D., Swetnam, J., Karasavvas, N., Michael, N. L., Kim, J. H., Marovich, M., & Cardozo, T. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108446 · Cited by 36
The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development
O’Connell, R. J., Kim, J. H., & Excler, J. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.951335 · Cited by 35
“The V1V2 scaffolds in complex with monoclonal antibodies have shown that V1V2 forms a four-stranded b sheet domain, in which sequence diversity and glycosylation are largely segregated to strand connecting loops [16].”
BackgroundMadani, N., Princiotto, A. M., Easterhoff, D., Bradley, T., Luo, K., Williams, W. B., Liao, H., Moody, M. A., Phad, G. E., Bernat, N. V., et al. (2016) · Journal of Virology · doi:10.1128/jvi.03211-15 · Cited by 35
Self-citationAntibodyomics: bioinformatics technologies for understanding B‐cell immunity to HIV ‐1
Kwong, P. D., Chuang, G., DeKosky, B. J., Gindin, T. S., Georgiev, I. S., Lemmin, T., Schramm, C. A., Sheng, Z., Soto, C. S., Yang, A., et al. (2017) · Immunological Reviews · doi:10.1111/imr.12480 · Cited by 38
“11,102 In Antibodyomics9, we extend this methodology to a surface-matrix approach in which a collection of individual surface mutations are generated and their properties are assessed (Fig.”
MethodSelf-citationNoy-Porat, T., Mechaly, A., Levy, Y., Makdasi, E., Alcalay, R., Gur, D., Aftalion, M., Falach, R., Ben‐Arye, S. L., Lazar, S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102479 · Cited by 36
HIV-1 Variable Loop 2 and its Importance in HIV-1 Infection and Vaccine Development
Rao, M., Peachman, K. K., Kim, J., Gao, G., Alving, C. R., Michael, N. L., & Rao, V. B. (2013) · Current HIV Research · doi:10.2174/1570162x113116660064 · Cited by 40
“V1V2 loop is also involved in the formation of quaternary epitopes [9, 13, 42] that are associated with many neutralizing antibodies as also was demonstrated by the crystal structure of the V1V2 domain of HIV-1 gp120 from two clade C strains, complexed with the Fab fragment of monoclonal antibody PG9 [43].”
BackgroundInfluentialYokoyama, M., Nomaguchi, M., Doi, N., Kanda, T., Adachi, A., & Sato, H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00110 · Cited by 36
“V1/V2 and V3 form flexible loop structures on the gp120 core region (Huang et al., 2005; McLellan et al., 2011) and have been shown to be involved in modulation of the co-receptor usage, cell tropism, replication ability and/or neutralization resistance (Freed and Martin, 1995, 2013; Clapham and…”
BackgroundMethodInfluentialRinge, R. P., Phogat, S. K., & Bhattacharya, J. (2012) · Virology · doi:10.1016/j.virol.2012.01.011 · Cited by 40
Self-citationTuning of glyconanomaterial shape and size for selective bacterial cell agglutination
Martín, J. J. C., Assali, M., Fernández‐García, E., Valdivia, V., Sánchez‐Fernández, E. M., Fernández, J. M. G., Wellinger, R. E., Fernández, I., & Khiar, N. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb02488a · Cited by 38
Protein design: from computer models to artificial intelligence
Paladino, A., Marchetti, F., Rinaldi, S., & Colombo, G. (2017) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1318 · Cited by 37
Zolla‐Pazner, S., Alvarez, R. A., Kong, X., & Weiß, S. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000551 · Cited by 35
Singh, A. A., Pooe, O. J., Kwezi, L., Lotter-Stark, T., Stoychev, S., Alexandra, K., Gerber, I. B., Bhiman, J. N., Vorster, J., Pauly, M. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63052-1 · Cited by 35
Neutralizing Antibodies Targeting HIV-1 gp41
Caillat, C., Guilligay, D., Sulbarán, G., & Weissenhorn, W. (2020) · Viruses · doi:10.3390/v12111210 · Cited by 46
Glycan reactive anti-HIV-1 antibodies bind the SARS-CoV-2 spike protein but do not block viral entry
Mannar, D., Leopold, K., & Subramaniam, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-91746-7 · Cited by 34
“Antibodies All anti-gp120 IgG antibodies were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (2G12) from Polymun Scientific, Anti-HIV-1 gp120 Monoclonal (PG9) from IAVI (cat# 12149), Anti-HIV-1 gp120 Monoclonal (PG16) from IAVI, Anti-HIV-1 gp120 Monoclonal (PGT…”
BackgroundMcKinley, S. A., Chen, A., Shi, F., Wang, S., Mucha, P. J., Forest, M. G., & Lai, S. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100598 · Cited by 35
Expressed IgH μ and τ transcripts share diversity segment in ranched Thunnus orientalis
Mashoof, S., Pohlenz, C., Chen, P. L., Deiss, T. C., Gatlin, D. M., Buentello, A., & Criscitiello, M. F. (2013) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2013.10.015 · Cited by 36
van Diepen, M. T., Chapman, R. E., Douglass, N., Galant, S., Moore, P. L., Margolin, E., Ximba, P., Morris, L., Rybicki, E. P., & Williamson, A. (2019) · Journal of Virology · doi:10.1128/jvi.02155-18 · Cited by 38
“Such antibodies typically recognize a lysine-rich region (residues 168 to 171) on Env and also interact with a glycan at N160 (78, 79, 88, 106).”
BackgroundMethodCimbro, R., Gallant, T., Dolan, M. A., Guzzo, C., Zhang, P., Lin, Y., Miao, H., Ryk, D. V., Arthos, J. A., Gorshkova, I. I., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314718111 · Cited by 34
“Liu L, Cimbro R, Lusso P, Berger EA (2011) Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV- 1 envelope glycoprotein trimer.”
MethodInfluentialSelf-citationRestricted N-glycan Conformational Space in the PDB and Its Implication in Glycan Structure Modeling
Jo, S., Lee, H. S., Skolnick, J., & Im, W. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002946 · Cited by 36
Vectored antibody gene delivery for the prevention or treatment of HIV infection
Deal, C. E., & Balazs, A. B. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000145 · Cited by 37
Toonstra, C., Amin, M. A., & Wang, L. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b01044 · Cited by 36
Self-citationLertjuthaporn, S., Cicala, C., Ryk, D. V., Liu, M., Yolitz, J., Wei, D., Nawaz, F., Doyle, A., Horowitch, B., Park, C., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007278 · Cited by 32
Self-citationAntibody responses to the HIV-1 envelope high mannose patch
Daniels, C. N., & Saunders, K. O. (2019) · Advances in immunology · doi:10.1016/bs.ai.2019.08.002 · Cited by 36
“Both V3-glycan and V1V2-glycan antibodies can bind the N156 glycan (Bonsignori et al., 2011; Garces et al., 2015, 2014; McLellan et al., 2011; Sok, Doores, et al., 2014; Walker et al., 2009), but V1V2-glycan antibodies will not be discussed here.”
BackgroundSapparapu, G., Czakó, R., Alvarado, G. S., Shanker, S., Prasad, B. V. V., Atmar, R. L., Estes, M. K., & Crowe, J. E. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005719 · Cited by 39
Ringe, R. P., Ozorowski, G., Yasmeen, A., Cupo, A., Portillo, V. M. C., Pugach, P., Golabek, M., Rantalainen, K. I., Holden, L. G., Cottrell, C. A., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00264-17 · Cited by 34
“in a way that better accommodates the CDR3 loops of PGT145 and other bNAbs that recognize this region of the trimer, which can be highly flexible (55).”
BackgroundSelf-citationHake, A., & Pfeifer, N. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005789 · Cited by 34
Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
Boyington, J. C., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Chen, M., Kong, W., Ngwuta, J. O., Thomas, P. V., Tsybovsky, Y., Yang, Y., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159709 · Cited by 34
“Fabs were created by digesting the IgG with Lys-C or HRV3C protease [24] , and the cleaved Fc region was removed by passing the mixture over Protein A agarose.”
MethodSelf-citationKirik, U., Persson, H., Levander, F., Greiff, L., & Ohlin, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01433 · Cited by 33
“For comparison with real protein structures, examples of structures with an origin in IGHV1-18 (PDB: 3SDY) (22), IGHV1-8 (PDB 3X3G and 3U1S) (23, 24), IGHV2-5 (PDB: 3QRG), IGHV3 subgroup (PDB: 2R56 and 3FZU) (25, 26), IGHV4-39 (PDB: 5C6T) (27), IGHV4-59 (PDB: 3HI1) (28), and IGHV5-51 (PDB: 4BUH) (29) were identified u…”
MethodKarch, C. P., Bai, H., Torres, O. B., Tucker, C., Michael, N. L., Matyas, G. R., Rolland, M., Burkhard, P., & Beck, Z. (2018) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.12.001 · Cited by 33
Glycosylation as a key parameter in the design of nucleic acid vaccines
Ozdilek, A., & Avci, F. Y. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102348 · Cited by 33
Cross-reactive broadly neutralizing antibodies: timing is everything
Euler, Z., & Schuitemaker, H. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00215 · Cited by 43
“…of gp120 V1V2 with PG9 revealed that this antibody as well as CH04 and PGT145 share a common mode of glycan penetration by extended anionic loops Frontiers in Immunology | HIV and AIDS July 2012 | Volume 3 | Article 215 | 4 “fimmu-03-00215” — 2012/7/19 — 20:32 — page 5 — #5 (McLellan et al., 2011).”
BackgroundBroadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives
Mahomed, S. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00152-22 · Cited by 42
Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth
Willis, J. R., Sapparapu, G., Murrell, S., Julien, J., Singh, V., King, H. G., Xia, Y., Pickens, J. A., LaBranche, C. C., Slaughter, J. C., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80693 · Cited by 33
“along with the native PG9 structure (PDB ID: 3U4E) (2).”
BackgroundResultInfluentialSelf-citationChemical Cross-Linking Stabilizes Native-Like HIV-1 Envelope Glycoprotein Trimer Antigens
Schiffner, T., de Val, N., Russell, R. A., de Taeye, S. W., de la Peña, A. T., Ozorowski, G., Kim, H. J., Nieusma, T., Brod, F., Cupo, A., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01942-15 · Cited by 32
Self-citationAcharya, P., Luongo, T. S., Louder, M. K., McKee, K., Yang, Y., Kwon, Y. D., Mascola, J. R., Kessler, P., Martin, L., & Kwong, P. D. (2013) · Structure · doi:10.1016/j.str.2013.04.015 · Cited by 34
“…domain, the bridging sheet, and the V1/V2 region, and these domains may adopt different relative spatial arrangements in response to ligand binding or oligomeric interactions within the functional viral spike (Chen et al., 2005, 2009; McLellan et al., 2011; Pancera et al., 2010; Zhou et al., 2007).”
BackgroundSelf-citationSun, M., Li, Y., Yuan, Z., Lu, W., Kang, G., Fan, W., & Li, Q. (2016) · Archives of Virology · doi:10.1007/s00705-016-2942-4 · Cited by 33
Crooks, E. T., Osawa, K., Tong, T., Grimley, S. L., Dai, Y. D., Whalen, R. G., Kulp, D. W., Menis, S., Schief, W. R., & Binley, J. Μ. (2017) · Virology · doi:10.1016/j.virol.2017.02.024 · Cited by 34
Self-citationLi, S. W., Yu, B., Byrne, G., Wright, M., O’Rourke, S. M., Mesa, K. A., & Berman, P. W. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27016 · Cited by 33
Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates
de Castro, I. S., Gorini, G., Mason, R. D., Gorman, J., Bissa, M., Rahman, M. A., Arakelyan, A., Kalisz, I., Whitney, S., Becerra‐Flores, M., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102047 · Cited by 29
Self-citationElicitation of HIV-1-neutralizing antibodies against the CD4-binding site
Georgiev, I. S., Joyce, M. G., Zhou, T., & Kwong, P. D. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328363a90e · Cited by 33
“On the unliganded spike (left image), only the outer domain and the V1/V2 regions are known [6-9], as the inner domain and bridging sheet regions likely assume conformations differ from those determined in currently available crystal structures [10-12].”
BackgroundSelf-citationJacob, R. A., Moyo-Gwete, T., Schomaker, M., Abrahams, F., Grau-Pujol, B., & Dorfman, J. R. (2015) · Journal of Virology · doi:10.1128/jvi.00129-15 · Cited by 31
Malherbe, D. C., Pissani, F., Sather, D. N., Guo, B., Pandey, S., Sutton, W. F., Stuart, A. B., Robins, H. S., Park, B. S., Krebs, S. J., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01812-14 · Cited by 35
“These characteristics include long CDR3 regions and extensive somatic hypermutation (27), surface quaternary epitopes formed by neighboring variable loops (28, 29), and exquisite simulation of interactions with CD4 (30).”
BackgroundJia, M., Liberatore, R. A., Guo, Y., Chan, K., Pan, R., Lü, H., Waltari, E., Mittler, E., Chandran, K., Finzi, A., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.024 · Cited by 39
Rathore, U., Saha, P., Kesavardhana, S., Kumar, A. A., Datta, R., Sankar, D. S., Das, R., Mascola, J. R., & Varadarajan, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.788919 · Cited by 36
Self-citationYuan, T., Li, J., & Zhang, M.-Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069789 · Cited by 47
Designing synthetic vaccines for HIV
Fernández‐Tejada, A., Haynes, B. F., & Danishefsky, S. J. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1027690 · Cited by 30
“This unexpected finding, which was not revealed by the original PG9 structural study [63], is consistent with a recent crystal structure of a scaffolded V1V2 domain/PG16 Fab complex [74] showing that PG16 interacts extensively with a sialylated hybrid N-glycan present at the secondary site (Asn(156) or Asn(173)).”
BackgroundResultSelf-citationLi, X., Grant, O. C., Ito, K., Wallace, A., Wang, S., Zhao, P., Wells, L., Lu, S., Woods, R. J., & Sharp, J. S. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b00888 · Cited by 30
Orwenyo, J., Cai, H., Giddens, J. P., Amin, M. A., Toonstra, C., & Wang, L. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00319 · Cited by 31
Self-citationAntibody-Mediated Catalysis in Infection and Immunity
Bowen, A. D., Wear, M. P., & Casadevall, A. (2017) · Infection and Immunity · doi:10.1128/iai.00202-17 · Cited by 31
Hioe, C. E., Kumar, R., Upadhyay, C., Jan, M., Fox, A., Itri, V., Peachman, K. K., Rao, M., Liu, L., Lo, N. C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02441 · Cited by 30
“Similarly, gp120A244/2158 V2i mAb showed increased reactivity with V2q mAb PG9, but immunization with this complex did not induce PG9-like or PG9-competing Abs.”
BackgroundResultInfluentialRasheed, M., Bettadapura, R., & Bajaj, C. (2015) · Structure · doi:10.1016/j.str.2015.03.026 · Cited by 34
“…of the new model forms 4 beta sheets between residues 126-178, which is similar to the conformations observed in 4NCO, 3J5M and 3U4E (Julien et al., 2013b; Lyumkis et al., 2013; McLellan et al., 2011) (note that the V1V2 conformation reported in (McLellan et al., 2011) does not include the core).”
BackgroundResultRole of IL-21 and IL-21 Receptor on B Cells in HIV Infection
Pallikkuth, S., Parmigiani, A., & Pahwa, S. G. (2012) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v32.i2.50 · Cited by 30
Goo, L., Jalalian‐Lechak, Z., Richardson, B. A., & Overbaugh, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.01414-12 · Cited by 36
“Two of the four PG9/16-resistant variants, isolated from subject QF495, did not have the full glycosylation sequon that is a target for these MAbs, despite having the N160 residue (20, 28).”
BackgroundInfluentialSmith, S. A., Burton, S. L., Kilembe, W., Lakhi, S., Karita, E., Price, M. A., Allen, S. A., Hunter, E., & Derdeyn, C. A. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005989 · Cited by 34
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Ahmed, Y., Tian, M., & Gao, Y. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0178-3 · Cited by 30
Crooks, E. T., Grimley, S. L., Cully, M. D., Osawa, K., Dekkers, G., Saunders, K. O., Rämisch, S., Menis, S., Schief, W. R., Doria‐Rose, N. A., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007024 · Cited by 32
Self-citationStanfield, R. L., Castro, C. D., Marzaioli, A. M., Wilson, I. A., & Pantophlet, R. A. (2014) · Glycobiology · doi:10.1093/glycob/cwu123 · Cited by 31
“2014), the PGT128 family that recognizes oligomannose-type glycans at positions 301 and 332 on gp120 (Pejchal et al. 2011), the PGT135 family that recognizes oligomannose-type glycans at positions 332, 392 and 295 and 386 depending on the isolate (Kong et al.”
BackgroundSelf-citationHIV vaccine design: the neutralizing antibody conundrum
Stamatatos, L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.006 · Cited by 32
Ivanochko, D., Fabra-García, A., Teelen, K., van de Vegte‐Bolmer, M., van Gemert, G., Newton, J. C., Semesi, A., de Bruijni, M. H. C., Bolscher, J. M., Ramjith, J., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.013 · Cited by 29
Self-citationCharacterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer
Nkolola, J. P., Bricault, C. A., Cheung, A., Shields, J. L., Perry, J., Kovacs, J. M., Giorgi, E. E., van Winsen, M., Apetri, A. C., der Linden, E. C. M. B.-V., et al. (2014) · Journal of Virology · doi:10.1128/jvi.01739-14 · Cited by 29
“PG9 and PG16 have been reported to bind preferentially to Env trimers and target V2 glycans (32, 33).”
BackgroundAlexander, J., Mendy, J., Vang, L., Avanzini, J. B., Garduño, F., Manayani, D. J., Ishioka, G. Y., Farness, P., Ping, L., Swanstrom, R. I., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082380 · Cited by 28
Self-citationNeutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas
Barbian, H. J., Decker, J. M., Bibollet‐Ruche, F., Galimidi, R. P., West, A. P., Learn, G. H., Parrish, N. F., Iyer, S. S., Li, Y., Pace, C. S., et al. (2015) · mBio · doi:10.1128/mbio.00296-15 · Cited by 33
Self-citationThe HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies
Klasse, P. J., Sanders, R. W., Ward, A. B., Wilson, I. A., & Moore, J. P. (2025) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01206-6 · Cited by 43
“In addition, the paratope contacts the N160 glycan on a second protomer 147,148 .”
Self-citationSampath, S., Carrico, C., Janes, J. H., Gurumoorthy, S., Gibson, C., Melcher, M., Chitnis, C. E., Wang, R., Schief, W. R., & Smith, J. D. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003420 · Cited by 33
Self-citationGlycoform and Net Charge Heterogeneity in gp120 Immunogens Used in HIV Vaccine Trials
Yu, B., Morales, J. F., O’Rourke, S. M., Tatsuno, G. P., & Berman, P. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043903 · Cited by 29
Toonstra, C., Wu, L. Y., Li, C., Wang, D., & Wang, L. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00145 · Cited by 30
Self-citationCommon helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions
Wibmer, C. K., Richardson, S. I., Yolitz, J., Cicala, C., Arthos, J. A., Moore, P. L., & Morris, L. (2018) · Nature Communications · doi:10.1038/s41467-018-06794-x · Cited by 26
Self-citationChuang, G., Lai, Y., Boyington, J. C., Cheng, C., Geng, H., Narpala, S., Rawi, R., Schmidt, S. D., Tsybovsky, Y., Verardi, R., et al. (2020) · Journal of Virology · doi:10.1128/jvi.00074-20 · Cited by 27
“25] [34, 35]), and the denominator was defined by the binding of antibody 447-52D, which only binds V3 region of Env in open configurations.”
BackgroundSelf-citationGoo, L., Milligan, C., Simonich, C. A. L., Nduati, R. W., & Overbaugh, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.00953-12 · Cited by 31
“For example, residue N160, which is required for PG9 neutralization (37, 71), was present in both F535 B and M, but only the former was neutralized by this MAb.”
BackgroundInfluentialYen, P.-J., Herschhorn, A., Haim, H., Salas, I., Gu, C., Sodroski, J., & Gabuzda, D. H. (2014) · Journal of Virology · doi:10.1128/jvi.02785-13 · Cited by 28
“Here, we removed the GAG linker and modeled an HIV V1/V2 domain structure containing the analogous N160 glycan (red) (24), based on the orientation of V1/V2 in the HIV Env trimer structure.”
BackgroundMethod
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.